28

nanotimes

Companies Facts

E Ink reported an EPS of NT$3.81, thanks to the fast- growing product demand, continuous R&D, and well executed cross-group synergy.

“In 2010 we achieved several key milestones,” said Dr. Scott Liu, Chairman, E Ink Holdings, Inc. “We tripled the number of ePaper displays as shipped in 2009 for the eReader market alone, launched two new ePaper display platforms, E Ink Pearl™ and E Ink Triton™ and we have had strong demand from the Tablet PC market for our FFS technology-based LCD products.” http://www.e-ink.com

E

PIR Technologies, Inc. have repeatedly fabricated high efficiency polycrystalline cadmium tellu-

ride (CdTe) solar cells on commercial glass sub- strates. According to Dr. Siva Sivananthan, founder and CEO of EPIR Technologies, “EPIR has been collaborating closely with a team of scientists from National Renewable Energy Laboratory (NREL). Toge- ther we developed a CdTe solar cell with a maximum of 15.2% efficiency.” Dr. Sivananthan added, “The combination of EPIR’s expertise in CdTe materials and NREL’s expertise in CdTe solar cell device tech- nology has empowered us to achieve these excellent results in a short timeframe.”

According to Dr. Chollada Gilmore, EPIR’s CdTe Solar Cell Technical Lead, “Our champion cell effici- ency was officially verified by NREL at 15.2 % effici- ency. The high efficiency was driven by a fill factor of 77.6%, which is one of the highest fill factor values ever recorded for this type of solar cell. These results are significant because our solar cells were fabrica- ted using inexpensive commercial TEC-series glass substrates as opposed to technical-grade glass which

is commonly used in champion cell fabrication.” EPIR Technologies, Inc. is a pioneer of single crystal II-VI photovoltaic materials and a global leader in the field of infrared sensors and imaging. http://www.epir.com

E

vonik Industries formally acquired the entire RESOMER®

business of Boehringer Ingelheim

Pharma GmbH & Co. KG on March 1, 2011. This acquisition involved transferring the entire product portfolio comprising standard and customer-specific polymers for medical applications and pharmaceuti- cal formulations to Evonik‘s Pharma Polymers Busi- ness Line.

The purchase agreement was signed in December 2010. Based on its polymer platform EUDRAGIT®

,

the Pharma Polymers Business Line is developing and researching customer-specific solutions for oral delivery forms. By acquiring the new RESOMER® Product Line, Pharma Polymers is opening up an application field in parenteral delivery forms, for example, for formulating innovative biotechnological active substances.

Furthermore, ACRIFIX® 1R 9019 Solar adhesive is

available immediately for bonding applications in furniture, store fixtures and exhibition stands. Evo- nik originally developed this product for use in solar applications of high requirements in terms of creating a premium appearance. ACRIFIX 1R 9019 Solar is a UV-curing polymerization adhesive. Its merits are that it is ideal for bonding large surfaces, geometri- cally complicated surfaces, T-joints and butt joints. http://www.evonik.com

11-02/03 :: February / March 2011